Christoph Röllig, Christoph Schliemann, Leo Ruhnke, Lars Fransecky, Björn-Niklas Heydrich, Maher Hanoun, Richard Noppeney, Kerstin Schäfer-Eckart, Knut Wendelin, Jan-Henrik Mikesch, Jan Moritz Middeke, Manja Reimann, Frank Fiebig, Sven Zukunft, Martin Wermke, Hubert Serve, Uwe Platzbecker, Carsten Müller-Tidow, Claudia D Baldus, Martin Bornhäuser
We conducted a phase I trial in newly diagnosed acute myeloid leukaemia (AML) to investigate the combination of two novel targeted agents, gemtuzumab ozogamicin (GO) and midostaurin, with intensive chemotherapy in FLT3-mutated AML and CBF leukaemia. Three dose levels of midostaurin and one to three sequential doses of 3 mg/m2 GO in combination with '7 + 3' induction were evaluated. Based on safety findings in 12 patients, our results show that 3 mg/m2 GO on Days 1 + 4 and 100 mg midostaurin on Days 8-21 can be safely combined with IC in newly diagnosed AML...
April 9, 2024: British Journal of Haematology